日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer

HER2阳性转移性乳腺癌患者一线接受帕妥珠单抗和曲妥珠单抗治疗后的真实世界治疗模式和结果

期刊:Oncology and Therapy
影响因子:3.2
doi:10.1007/s40487-023-00241-8
Mehta, Sandhya; Xie, Jipan; Ionescu-Ittu, Raluca; Nie, Xiaoyu; Kwong, Winghan J
肿瘤免疫
HER2
肿瘤
乳腺癌
发表日期：2023
文献求助 收藏

Understanding the Effect of Osteoarthritis on Surgical Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients With Tenosynovial Giant Cell Tumors

了解骨关节炎对腱鞘巨细胞瘤患者的手术治疗模式、医疗资源利用和费用的影响

期刊:Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews
影响因子:2.1
doi:10.5435/JAAOSGlobal-D-23-00047
Lin, Feng; Wilson, Kathleen; Kwong, Winghan J; Abraham, John A
关节炎
细胞生物学
发表日期：2023
文献求助 收藏

Patient-Reported Outcomes After Ferric Carboxymaltose Treatment for Iron Deficiency Anemia: A Prospective Observational Study

铁羧基麦芽糖治疗缺铁性贫血后患者报告结局：一项前瞻性观察研究

期刊:International Journal of General Medicine
影响因子:2
doi:10.2147/IJGM.S413105
Kwong, Winghan J; Numan, Syed; Hunter, Tina D; Alves, Dalila; Patel, Anish; Shanbhag, Satish
贫血
代谢
发表日期：2023
文献求助 收藏

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States

美国HER2阳性转移性乳腺癌（mBC）患者接受Ado-Trastuzumab Emtansine（T-DM1）治疗及后续治疗的疗效回顾性观察研究

期刊:Drugs-Real World Outcomes
影响因子:1.9
doi:10.1007/s40801-022-00340-4
Denduluri, Neelima; Espirito, Janet L; Hackshaw, Michelle D; Wentworth, Chuck; Recchia, Tamy; Kwong, Winghan J
肿瘤免疫
HER2
肿瘤
乳腺癌
发表日期：2023
文献求助 收藏

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA

美国转移性胃癌患者一线曲妥珠单抗治疗后的真实世界治疗模式和经济负担

期刊:Drugs-Real World Outcomes
影响因子:1.9
doi:10.1007/s40801-023-00378-y
Barzi, Afsaneh; Lin, Feng; Song, Jinlin; Lam, Clara; Nie, Xiaoyu; Noman, Ahmed; Kwong, Winghan J
胃癌
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study

依度沙班治疗可提高治疗满意度并减少医疗资源利用：来自依度沙班与华法林治疗心房颤动患者（ENSURE-AF）研究的分析

期刊:Europace
影响因子:7.4
doi:10.1093/europace/euy141
Goette, Andreas; Kwong, Winghan J; Ezekowitz, Michael D; Banach, Maciej; Hjortshoj, Soren P; Zamoryakhin, Dmitry; Lip, Gregory Y H
发表日期：2018
文献求助 收藏

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial

自发性颅外出血事件对房颤患者健康状态效用的影响：ENGAGE AF-TIMI 48 试验的结果

期刊:Journal of the American Heart Association
影响因子:5.3
doi:10.1161/JAHA.117.006703
Wang, Kaijun; Li, Haiyan; Kwong, Winghan J; Antman, Elliott M; Ruff, Christian T; Giugliano, Robert P; Cohen, David J; Magnuson, Elizabeth A
ENG
TIM
发表日期：2017
文献求助 收藏

Impact of atrial fibrillation on stroke-related healthcare costs

心房颤动对中风相关医疗保健成本的影响

期刊:Journal of the American Heart Association
影响因子:5.3
doi:10.1161/JAHA.113.000479
Sussman, Matthew; Menzin, Joseph; Lin, Iris; Kwong, Winghan J; Munsell, Michael; Friedman, Mark; Selim, Magdy
中风
心血管
发表日期：2013
文献求助 收藏

All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation

接受华法林治疗的房颤患者的全因医疗保健费用和出血相关医疗保健费用

期刊:
影响因子:
doi:10.18553/jmcp.2011.17.9.672
Ghate, Sameer R; Biskupiak, Joseph; Ye, Xiangyang; Kwong, Winghan J; Brixner, Diana I
发表日期：2011
文献求助 收藏